U.S. Biotech Firms Look Abroad for Drug Trials Amid FDA Shake-Up

Several American biotech companies are exploring options to move early-stage clinical trials of new drugs outside the United States, citing growing concerns over delays at the U.S. Food and Drug Administration (FDA).

Recent policy changes and large-scale layoffs under the Trump administration have affected key FDA departments responsible for reviewing new treatments. Executives and industry experts say these disruptions could slow down the drug approval process, prompting some firms to consider more stable regulatory environments in countries like Australia and those in the European Union.

Traditionally, the FDA has been the gold standard for regulatory approval due to its global reputation and access to the lucrative U.S. market. But the current uncertainty is pushing smaller biotech companies to diversify their trial locations to avoid delays and ensure continued progress in drug development.

Industry consultants have reported a noticeable rise in inquiries about setting up clinical trials abroad. Some firms are already initiating parallel studies in other countries to minimize risks and maintain development timelines.

U.S. Health Secretary Robert F. Kennedy Jr. is expected to defend the changes as part of a broader plan to improve agency efficiency and reduce conflicts of interest. However, the shake-up could have long-term implications for America’s role in the global pharmaceutical landscape.